Renewed Hope For Mild Alzheimer’s Patients As NICE Process On Anti-Dementia Medicines Ruled Unfair, UK

Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, welcomed today’s landmark ruling by the Court of Appeal. The Court found that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer’s disease was procedurally unfair.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on May 15th, 2008